Testosterone and the prostate: Implications for the treatment of hypogonadal men

Current Urology Reports

Volumn 9, Issue 6, 2008, Pages 500-505

  Holyoak, Joshua D ^a   Crawford, E David ^b   Meacham, Randall B ^b  

^a UNIVERSITY OF MISSOURI   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DUTASTERIDE; FINASTERIDE; PLACEBO; TESTOSTERONE;

ANDROGEN THERAPY; CANCER GROWTH; CANCER RISK; DISEASE EXACERBATION; HUMAN; HYPOGONADISM; MALE; PATHOPHYSIOLOGY; PROSTATE; PROSTATE CANCER; PROSTATE HYPERTROPHY; REVIEW; TESTOSTERONE BLOOD LEVEL;

HUMANS; HYPOGONADISM; MALE; PROSTATE; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; TESTOSTERONE;

EID: 57749088367     PISSN: 15272737     EISSN: 15346285     Source Type: Journal    
DOI: 10.1007/s11934-008-0085-1     Document Type: Review

References (39)

1. Wang C, Cunningham G, Dobs A, et al.: Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. J Clin Endocrinol Metab 2004, 89:2085-2098.
2. Barqawi A, Crawford ED: Testosterone replacement therapy and the risk of prostate cancer: is there a link? Int J Impot Res 2006, 18:323-328.
3. • Rohrmann S, Nelson WG, Rifai N, et al.: Serum sex steroid hormones and lower urinary tract symptoms in third national health and nutrition examination survey (NHANES III). Urology 2007, 69:708-713. A large cross-sectional study elucidating the effects of prostatic androgens and estrogens on lower urinary tract symptoms.
4. AUAnet. Clinical guidelines. Management of erectile dysfunction ('05/Updated '06). Available at http://www.auanet.org/guidelines/edmgmt.cfm. Accessed June 2008.
5. Harman SM, Metter EJ, Tobin JD, et al.: Longitudinal effects of aging on serum total and free testosterone levels in healthy men: Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab 2001, 86:724-731.
6. • Jockenhovel F, Kaufman JM, Mickisch GH, et al.: The good, the bad, and the unknown of late onset hypogonadism: the urological perspective. J Men's Health Gender 2005, 2:292-301. A thorough review of the implications of late-onset hypogonadism.
7. Isaacs JT: Testosterone and the prostate. In Testosterone: Action, Deficiency, Substitution. 3rd ed. Edited by Nieschlag E, Behre HM. Cambridge: Cambridge University Press; 2004:347-374.
8. Huggins C, Hodges CV: Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941 [Reprint of historical article]. J Urol 2002, 168:9-12.
9. Jemal A, Siegel R, Ward E, et al.: Cancer statistics, 2008. CA Cancer J Clin 2008, 58:71-96.
10. Berry SJ, Coffey DS, Walsh PC, Ewing LL: The development of human benign prostatic hyperplasia with age. J Urol 1984, 132:474-479.
11. Behre HM, Bohmeyer J, Nieschlag E: Prostate volume in testosterone-treated and untreated hypogonadal men in comparison to age-matched normal controls. Clin Endocrinol (Oxf) 1994, 40:341-349.
12. • Marks LS, Mazer NA, Mostaghel E, et al.: Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. JAMA 2006, 296:2351-2361. Level I evidence regarding the effects of exogenous testosterone administration on the microscopic environment of the prostate.
13. Gray A, Feldman HA, McKinlay JB, Longcope C: Age, disease, and changing sex hormone levels in middle-aged men: results of the Massachusetts Male Aging Study. J Clin Endocrinol Metab 1991, 73:1016-1025.
14. Gormley GJ, Stoner E, Bruskewitz RC, et al.: The effect of finasteride in men with benign prostatic hyperplasia. N Engl J Med 1992, 327:1185-1191.
15. Schatzl G, Brossner C, Schmid S, et al.: Endocrine status in elderly men with lower urinary tract symptoms: correlation of age, hormonal status, and lower urinary tract function. Urology 2000, 55:397-402.
16. Schatzl G, Reiter WJ, Thurridl T, et al.: Endocrine patterns in patients with benign and malignant prostatic diseases. Prostate 2000, 44:219-224.
17. Basaria S, Dobs AS: Risks versus benefits of testosterone therapy in elderly men. Drugs Aging 1999, 15:131-142.
18. Morales A: Androgen replacement therapy and prostate safety. Eur Urol 2002, 41:113-120.
19. Foley CL, Kirby RS: 5-alpha-reductase inhibitors: what's new? Curr Opin Urol 2003, 13:31-37.
20. Marberger M, Roehrborn CG, Marks LS, et al.: Relationship among serum testosterone, sexual function, and response to treatment in men receiving dutasteride for benign prostatic hyperplasia. J Clin Endocrinol Metab 2006, 91:1323-1328.
21. Rhoden EL, Morgentaler A: Risks of testosterone-replacement therapy and recommendations for monitoring. N Engl J Med 2004, 350:482-492.
22. Bhasin S, Bremner WJ: Clinical review 85: Emerging issues in androgen replacement therapy. J Clin Endocrinol Metab 1997, 82:3-8.
23. Dean JD, Carnegie C, Rodzvilla J Jr, Smith T: Long-term effects of Testim 1% testosterone gel in hypogonadal men. Rev Urol 2004, 6:S22-S29.
24. Hajjar RR, Kaiser FE, Morley JE: Outcomes of long-term testosterone replacement in older hypogonadal males: a retrospective analysis. J Clin Endocrinol Metab 1997, 82:3793-3796.
25. Hermann M, Berger P: Hormone replacement in the ageing male? Exp Gerontol 1999, 34:923-933.
26. American Association of Clinical Endocrinologists: American Association of Clinical Endocrinologists medical guidelines for clinical practice for the evaluation and treatment of hypogonadism in adult male patients - 2002 update. Endocr Pract 2002, 8:439-456.
27. Morales A, Lunenfeld B: Investigation, treatment and monitoring of late-onset hypogonadism in males: official recommendations of the International Society for the Study of the Aging Male (ISSAM). Aging Male 2002, 5:74-86.
28. Hayes FJ: Androgen replacement in the male: recent studies. Curr Opin Endocrinol Diabetes 2001, 8:301-306.
29. Massengill JC, Sun L, Moul JW, et al.: Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy. J Urol 2003, 169:1670- 1675.
30. Hoffman MA, DeWolf WC, Morgentaler A: Is low serum free testosterone a marker for high grade prostate cancer? J Urol 2000, 163:824-827.
31. Chen SS, Chen KK, Lin AT, et al.: The correlation between pretreatment serum hormone levels and treatment outcome for patients with prostatic cancer and bony metastasis. BJU Int 2002, 89:710-713.
32. Ribeiro M, Ruff P, Falkson G: Low serum testosterone and a younger age predict for a poor outcome in metastatic prostate cancer. Am J Clin Oncol 1997, 20:605-608.
33. Schatzl G, Madersbacher S, Thurridl T, et al.: High-grade prostate cancer is associated with low serum testosterone levels. Prostate 2001, 47:52-58.
34. Morgentaler A, Bruning CO 3rd, DeWolf WC: Occult prostate cancer in men with low serum testosterone levels. JAMA 1996, 276:1904-1906.
35. Rhoden EL, Morgentaler A: Testosterone replacement therapy in hypogonadal men at high risk for prostate cancer: results of 1 year of treatment in men with prostatic intraepithelial neoplasia. J Urol 2003, 170:2348-2351.
36. Gerstenbluth RE, Maniam PN, Corty EW, Seftel AD: Prostate-specific antigen changes in hypogonadal men treated with testosterone replacement. J Androl 2002, 23:922-926.
37. Bhasin S, Singh AB, Mac RP, et al.: Managing the risks of prostate disease during testosterone replacement therapy in older men: recommendations for a standardized monitoring plan. J Androl 2003, 24:299-311.
38. Kaufman JM, Graydon RJ: Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men. J Urol 2004, 172:920-922.
39. Sarosdy MF: Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy. Cancer 2007, 109:536-541.